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Cell surface trafﬁckingProteolysis of transmembrane molecules is an irreversible post-translational modiﬁcation enabling autocrine,
paracrine and endocrine signaling of many cytokines. The pro-inﬂammatory activities of membrane bound TNFα
(pro-TNFα) strongly depend on ectodomain shedding mediated by the A Disintegrin And Metalloprotease family
member ADAM17. Despite thewell-documented role of ADAM17 in pro-TNFα cleavage during inﬂammation, little
is known about its regulation. Mitogen-activated protein kinase-induced phosphorylation of the ADAM17
cytoplasmic tail has been described to be required for proper activation. To address, if pro-TNFα shedding depends
on cytosolic phosphorylation we analyzed ADAM17 mutants lacking the cytoplasmic domain. ADAM17 mediated
shedding of pro-TNFα was induced by PMA, Anisomycin and the phosphatase inhibitors Cantharidin and
Calyculin A. Deletion of the entire cytoplasmic portion of ADAM17 abolished furin-dependent proteolytic
maturation and pro-TNFα cleavage. Interestingly, we could exclude that resistance to proconvertase processing
is the reason for the enzymatic inactivity of ADAM17 lacking the cytoplasmic portion as furin-resistant ADAM17
mutants rescued genetic ADAM17 deﬁciency after mitogen-activated protein kinase activation. Adding only 6
cytoplasmic amino acids completely restored ADAM17 maturation and shedding of pro-TNFα as well as of
both TNF-receptors Finally, we showed that a pro-TNFαmutant lacking the cytoplasmic portion was also shed
from the cell surface. We conclude that pro-TNFα cleavage by its major sheddase ADAM17 does not depend
on cytosolic phosphorylation and/or interaction. These results have general implications on understanding the
activation mechanism controlling the activity of ADAM17.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
ADAM-mediated proteolysis of transmembrane proteins emerges as
a key regulatory event in several signal transduction pathways, which
are critically involved in proliferation, differentiation, migration and
cell adhesion [1–3]. Among the 21 human and 37 mouse ADAM genestease; TNF-α, Tumor Necrosis
tor; PMA, phorbol 12-myristate
imide; GPI, glycosylphospha-
F, murine embryonic ﬁbroblast;
ellular domain
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e-John).
ights reserved.the closely related family members ADAM10 and ADAM17 represent
the best characterized sheddases in vivo [4,5]. ADAM17 was identiﬁed
as the main Tumor Necrosis Factor (TNF)α processing enzyme [6,7].
Genetic ADAM17 deletion in neutrophils and leukocytes mediates
resistance to otherwise lethal septic shock and bacterial-induced
peritonitis [8,9]. Therefore, ADAM17 activity was considered to promote
pro-inﬂammatory signaling events by cleaving the membrane-tethered
pro-TNFα and releasing the active cytokine. ADAM17−/− mice suffer
from severe developmental dysfunctions resulting in perinatal lethality
[6,10]. In recent studies it was demonstrated that ADAM17 activity is
essential for proper resolution of dextran-sodium sulfate (DSS)-induced
colonic inﬂammation by promoting TGFα cleavage and subsequent
Epidermal Growth Factor Receptor (EGFR) signaling indicating an anti-
inﬂammatory function of ADAM17 [11–13]. To date, over 74 cell surface
proteins have been reported to serve as ADAM17 substrates at least
in vitro, implicating a prominent contribution of ADAM17 to the secretory
proﬁle of several cell types [14]. Regulatory mechanisms leading to
ADAM17 activation and substrate recognition are not understood
in detail, but inside-out signaling via phosphorylation of the cytoplasmic
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considered as crucial steps [14,15]. Several kinases have been proposed
to phosphorylate ADAM17, including protein kinase C (PKC), protein
kinase G (PKG), extracellular-signal regulated kinase (ERK), p38-
mitogen-activated protein kinase (p38-MAPK) and phosphoinositide-
dependent kinase 1 (PDK1) [16–22]. Phosphorylation of threonine
(T735) can rapidly activate the sheddase activity of ADAM17 possibly
by the translocation from the Golgi network to the cell surface where
the primary site of ADAM17 activity is reported [22]. In a similar
approach, pharmacological inhibition of tyrosine — as well as serine/
threonine phosphatases resulted in strong increase of ADAM17 activity
[17,23]. Xu et al. provided evidence that the cytoplasmic tail of
ADAM17 supports cell surface homo-dimerization and association with
the natural inhibitor TIMP-3 [20]. However, there is controversy as to
whether the 133-amino acid long cytoplasmic portion of ADAM17 has
regulatory functions and controls sheddase activity. “Complementation
studies” with ADAM17 deﬁcient cells reconstituted with truncated
ADAM17 lacking the intracellular portion demonstrated that stimulation
of ADAM17 activitywas independent of the cytoplasmic portion [24–29].
Interestingly, chimeric fusion proteins of the extracellular portion of
ADAM17 and the transmembrane and cytoplasmic domains of the
ADAM17 substrate L-selectin showed impaired shedding activity after
stimulationwith various compounds indicating that the transmembrane
domain is important for ADAM17 activity and regulation [25].
A prerequisite for ADAM17 activation is the proteolytic removal of
the amino-terminal inhibitory prodomain by furin-like convertases
and consequently, the puriﬁed prodomain of ADAM17 represents
a speciﬁc ADAM17 inhibitor [30,31]. In a previous study it was
demonstrated that blocking pro-protein convertases did not affect
constitutive and rapid stimulation of ADAM17 [25]. Interestingly, in
mice lacking the inactive rhomboid protease iRhom2, TNFα shedding
is abolished due to an ADAM17 trafﬁcking- and maturation-defect
[16,32,33].
Themain goal of the current studywas to deﬁne if post-translational
alterations of ADAM17 or TNFα affect pro-TNFα release from the cell
surface thereby enabling systemic TNF-signaling. Based on previous
studies we designed two ADAM17 mutants lacking the cytoplasmic
domain termed ADAM17ΔCT [27] and ADAM17Δ700 [25] with an
only 6 amino acid long cytoplasmic tail. We compared the biochemical
functions of these mutants in terms of enzymatic activity, dimerization,
intracellular maturation and transport. Interestingly, it has been
realized that pro-TNFα also functions as a receptor transducing signals
into the TNFα-producing cells — a process referred to as “reverse
signaling”. How the short cytoplasmic domain of TNFα initiates
downstream effects at the molecular level has not been fully
elucidated yet but phosphorylation within the cytoplasmic portion
was suggested to be involved in TNFα reverse signaling [34–37]. The
impact of pro-TNFα phosphorylation in terms of ADAM17-mediated
proteolysis has not been addressed so far. Therefore we designed a
TNFα mutant lacking the cytoplasmic portion and monitored MAPK
induced proteolysis.
We could show that truncation of ADAM17 after aspartate 699
(ADAM17Δ700) did not signiﬁcantly impair ADAM17 activity after
induction of various signaling pathways, which have not been
addressed so far. Interestingly, complete deletion of the cytoplasmic
domain (ADAM17ΔCT) resulted in inactivation of ADAM17 without
interfering with the subcellular localization and dimerization potential
of the enzyme. Moreover, we show that the inactive ADAM17ΔCT
mutant is not processed by furin convertases. Surprisingly, prodomain
cleavage was not essential for ADAM17-stimulated TNFα shedding
after activation of intracellular serine/threonine kinases. Our data
provide evidence that proteolytic release of the main ADAM17
substrate TNFα is strongly stimulated by activation of serine/threonine
kinases but is largely independent of direct phosphorylation of its own
cytoplasmic portion or the cytoplasmic portion of the main sheddase
ADAM17.2. Materials and methods
2.1. Expression vectors, reagents and antibodies
Expression plasmids encoding murine ADAM17ΔCT (=
ADAM17Δ694), ADAM17Δ700 and ADAM17Δ735 were constructed
via PCR from pcDNA3.1(+)mADAM17 template plasmid. The numbers
indicate the ﬁrst missing amino acid of murine ADAM17. All constructs
were cloned in the retroviral vector pQCXIH. The plasmids encoding
murine iRhom2 and TNFα were ampliﬁed from murine spleen cDNA
and were further cloned into the pcDNA3.1(+) and pQCXIP expression
vectors. Murine ADAM17 and ADAM17ΔCT, both lacking the stop
codon, were cloned into the Gateway© shuttle vector pENTR4. The
cDNAs were then subcloned using homologous recombination into
the destination vectors pSPICA-C1 and C2 that contain the split
luciferase fragments 1 and 2, respectively, located 3′ of the Gateway©
recombination sites (Invitrogen, Karlsruhe, Germany). All coding
sequences were veriﬁed by DNA sequencing. The furin-resistant
ADAM17 mutants ADAM17AGAG and ADAM17RVNG were generated by
site-directed mutagenesis using the Phusion-Polymerase site-directed
mutagenesis kit according the manufacturer's instructions (Thermo
Scientiﬁc, Dreieich, Germany). We used the pQCXIH-mADAM17 vector
as template and the following primer for the mutagenesis PCR: A17-
RVNG_UP [5′-GAG TTT GTT CGT CGA GTG AAC GGA CGA GCT GAA CCT
AAC-3′], A17-AGAG_UP [5′-GAG TTT GTT CGT GCC GGA GCT GGT CGA
GCT GAA CCT AAC-3′] and A17-RVKR_DN (for both constructs)
[5′-TTC AGA TGG CTC TCT GTC TAT GAG CCC TTT TGG AAG-3′].
ADAM17-GPI was generated by three overlapping PCR steps using the
same forward primer [5′-GAT CCG TAC GTC GAT GCA GAG CAA AAG
AAC-3′] and three reverse primers encoding the GPI-signal of TRAIL;
GPI_DN_1 [5′-GTA ATG AGA AGA GGC AGG AGT CCC CGG GCT GGT
GGT CAT ATC TGC CAG AAA CTT CCC AAA AGT G-3′]; GPI_DN_2
[5′-CAA TTA GAA CTA TGA TCC CTA CGA TGG TGC ATG AGA GGT AAT
GAG AAG AGG CAG GAG TCC C-3′]; GPI_DN_3 [5′-GAT CGC GGC CGC
CTA AAC AAA CAC AAT CAG AAG CAC AAT TAG AAC TAT GAT CCC TAC
GAT GG-3′].
The expression plasmid encoding pro-TNFαΔNT was constructed
via PCR from pcDNA3.1(+)mTNFα template plasmid. The deletion
encompassing the intracellular portion was located N-terminally to
arginine-28.
The following reagentswere used: PMA, Anisomycin, Concanavalin A,
Cantharidin, Calyculin A and Cycloheximide (Sigma-Aldrich, Steinheim,
Germany); Protein-G-Sepharose (GE-Healthcare, Chalfont St Giles, UK);
Protein G Dynabeads (Life Technologies, Carlsbad, Germany); protease
inhibitor cocktail (Roche, Basel, Switzerland); 1.10-phenanthroline
(Calbiochem, Darmstadt, Germany), the hydroxamate based ADAM
inhibitors GW208264 and GI254023 were synthesized by Iris Biotech,
Marktredwitz, Germany.
The following antibodies were used: anti-ADAM17 (10.1) for
Western blot analysis (polyclonal antibody against the extracellular
portion of murine ADAM17, generated by Pineda Antikörper-Service,
Berlin, Germany), anti-ADAM17 (K133) for IP, ﬂow cytometry and CLSM
(generated by Dr. Friedrich Koch-Nolte, UKE Hamburg, Germany), anti-
actin (Sigma-Aldrich, Steinheim, Germany), anti-TNFα raised against
the N-terminal portion for Western blot (kindly provided by Dr. Bernd
Schröder, CAU Kiel, Germany), goat anti-TNFα for ﬂow cytometry
(R&D Systems, Wiesbaden, Germany), anti-KDEL (Enzo, Farmingdale,
NY, USA), anti-rabbit-POD and anti-mouse-POD (Thermo Scientiﬁc,
Dreieich, Germany), anti-goat-A647, anti-rabbit-A488 and anti-mouse-
A594 (Invitrogen, Karlsruhe, Germany).
2.2. Cell culture, transfection and retroviral transduction
Murine embryonic ﬁbroblasts (mEFs) were isolated from E13.5
ADAM17ex/ex embryos and immortalized with the SV40 large T antigen,
as previously described [13]. ADAM17−/− mEFs were isolated from
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Dr. Paul Saftig (CAU Kiel, Germany). HEK, mEF cells as well as Phoenix
cells were cultured in Dulbecco's modiﬁed Eagle's medium (DMEM)
with 10% fetal bovine serum (PAA, Cölbe, Germany).
HEK, NIH3T3 and Phoenix cells were transiently transfected
with Turbofect (Thermo Scientiﬁc, Dreieich, Germany) according to
manufacturer's instructions. Retroviruses were generated in Phoenix
cells. mEF cells isolated from ADAM17ex/ex or ADAM17−/− cells were
incubated with Phoenix cell supernatants, which were previously
transfected with the gene of interest. Subsequently the Phoenix cell
supernatantswereﬁltered,mixedwith Polybrene (8μg/ml) and directly
incubated with the target cells. The sedimentation of the viral particles
was achieved by a centrifugation step at 1000 ×g for 2 h at room
temperature (RT). After two days the antibiotics Hygromycin B
(50 μg/ml) or Puromycin (3μg/ml) were added to select stable clones.
2.3. Enzyme-linked immunosorbent assay (ELISA)
250,000 cells per well were seeded in a 12-well-plate. 24h later, the
cells were stimulated for the indicated time points with PMA (200nM),
Anisomycin (2 μM), Cantharidin (500 μM) or Calyculin A (40 nM).
Soluble cytokines and cytokine receptors (TNFα, TNFRI and TNFRII)
were measured by ELISA in cell-free culture supernatants according
the manufacturer's instructions. All ELISA kits were purchased from
R&D Systems, Wiesbaden, Germany.
2.4. Flow cytometry
Cells were seeded at a density of 250,000 cells per well in a 12-well-
plate. 24h later, cells were stimulated for the indicated time points with
PMA (200 nM) and/or Cycloheximide (CHX, 100 μM). Cells were
mechanically detached and washed three times with ice-cold PBS. Cell
suspensions were blocked for 15 min in PBS containing 10% BSA,
incubated for 1 h at 4 °C with primary antibody in PBS containing 1%
BSA, washed twice with PBS, stained for 30 min with secondary
antibody in PBS containing 1% BSA, washed twice again and analyzed
by ﬂow cytometry (FACS Canto I, BD Bioscience, San Jose, CA, USA).
For the detection of ADAM17, the polyclonal K133 antibody was used
(10 μg/ml). For the detection of pro-TNFα the goat anti-TNFα antibody
was used (1.5 μg/ml, R&D Systems, Wiesbaden, Germany).
2.5. Immunoﬂuorescence analysis
mEF cells were seeded at a density of 50,000 cells per well in a 12-
well-plate on glass cover slips. 24 h later, cells were treated with PMA
(200 nM) or Anisomycin (2 μM) for the indicated time points. Cells
were washed three times with PBS, ﬁxed with 4% Paraformaldehyde/
PBS for 20 min at room temperature. Fixed cells were permeabilized
for 5 min with PBS containing 0.2% Saponin and blocked for 1 h at
37 °C in staining buffer (PBS containing 3% BSA and 0.2% Saponin). The
primary antibodies were diluted 1:100 and incubated overnight at
4 °C in staining buffer. Afterwards the cover slips were washed 3 times
with PBS, stained for 1 h at RT with secondary antibody (1:100) in
staining buffer, washed twice and ﬁnally stained with DAPI solution.
Stained cover slipsweremounted inMountingMedium(Dako,Hamburg,
Germany), viewed and photographed with an FV1000 confocal laser
scanning microscope (Olympus, Tokyo, Japan) equipped with a U Plan S
Apo 100× oil immersion objective (N.A. 1.40). Digital images were
processed and merged using FV10-ASW 2.0 Viewer (Olympus, Tokyo,
Japan).
2.6. Western blot analysis
Cells of interest were washed with ice-cold PBS, scraped off culture
dishes and lysed in NP-40 lysis buffer (50 mM Tris, pH 7.4, 150 mM
NaCl2, 2 mM EDTA, 1% NP-40 (v/v) plus complete protease inhibitorcocktail and 10mM 1.10-phenanthroline). Western blots presented in
Fig. 3A as well as Fig. 4B were performed with lysates where the
NP-40 lysis buffer was supplemented with 10 μM marimastat to
prevent ADAM17-dependent autocatalysis. Debris were pelleted by
one centrifugation step (15,000 ×g, 4 °C, 15 min). Equal amounts of
total protein were used for lysate analysis. Aliquots of cell lysates
were incubated with SDS sample buffer (0.625 M Tris–HCl, pH 6.8,
2% SDS, 10% glycerol, 5% β-mercaptoethanol) and proteins were
heat inactivated for 10 min at 90 °C. Alternatively, samples were
incubated with SDS-sample buffer without β-mercaptoethanol. If
mentioned, glycoproteins were concentrated by applying 30 μl of
Concanavalin A beads (Sigma-Aldrich, Steinheim, Germany) directly
to the cell lysate. Protein concentration was determined by BCA assay
(Thermo Scientiﬁc, Dreieich, Germany). Proteins were separated by
SDS-PAGE and transferred to PVDF-membranes (Millipore, Darmstadt,
Germany).
2.7. Immunprecipitations
Cells were lysed in IP-Lysis buffer (10mMHEPES, 1mMEGTA, 1mM
EDTA, 10mM KCl, 0.5% NP-40, 1× complete protease inhibitor cocktail,
1.10 phenanthroline). Lysates were incubated with 1 μg antibody
overnight at 4 °C. The Protein G Dynabeads were blocked in PBS
containing 1% BSA overnight at 4 °C. After 24 h the beads were added
to the lysate-antibody solution and incubated for 1 h at RT. The beads
washed 3 times and prepared for further analyses.
2.8. Deglycosylation analysis
2–3×107 mEF cells were lysed for 1 h at 4 °C in IP-Lysis buffer and
ADAM17 was precipitated as described above. Sepharose beads
were denatured at 100 °C for 10 min in 1× Deglycosylation Lysis
buffer (New England Biolabs, Ipswich, MA, USA) and treated with
PNGaseF or EndoH according to the manufacturer's instructions (New
England Biolabs, Ipswich, MA, USA).
2.9. Furin in-vitro cleavage
2–3×107 mEF cells were lysed for 1 h at 4 °C in IP-Lysis buffer and
ADAM17 was precipitated as described above. Protein G-Dynabeads
were solved in furin Assay Buffer (100mM HEPES, 1mM CaCl2, 1mM
β-mercaptoethanol, 0.5% Triton X-100) and treated with recombinant
furin (1 U) for 2 h according to the manufacturer's instructions (New
England Biolabs, Ipswich, MA, USA).
2.10. Life cell activity assay
Equal amounts of HEK cells were seeded in a 24 well plate and cells
were grown DMEM with 10% FCS until 90% conﬂuency. Cell culture
medium was removed and cells were rinsed once with PBS to remove
traces of FCS. The activity of ADAM17 was determined using 10 mM
of the quenched ﬂuorogenic peptide MCA-PLAQAV(Dpa)RSSSR-NH
(Calbiochem, Darmstadt, Germany) in DMEM. The cleavage reaction
was initiated by the addition of 10 mM of the quenched ﬂuorogenic
peptide. The change in the ﬂuorescence was monitored over a time
period of 50 min (every minute) to characterize the enzyme activity.
Enzyme activity was measured with the ﬂuorescent spectrometer
Tecan Inﬁnite 200 Pro (Tecan, Männedorf, Switzerland) and proteolytic
activity was calculated from the emission at 405nm with an excitation
at 320nm.
2.11. Luciferase assay
HEKorNIH3T3 cellswere seeded at a density of 200,000 cells per 12-
well-plates. 24h later, cells were transiently transfected with Turbofect
(Thermo Scientiﬁc, Dreieich, Germany) and the ADAM17-Luciferase
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two days after transfection. Cells were detached and washed once with
PBS, resuspended in 100 μl 1× lysis buffer (Thermo Scientiﬁc, Dreieich,
Germany) and incubated for 15 min at RT. 20 μl of lysate was
transferred to a white 96 well plate and analyzed in a GloMax® 96
microplate Luminometer (Promega, Fitchburg, MA, USA). During the
measurement 50 μl of Coelenterazine solution (Promega, Fitchburg,
MA, USA) was added to the lysates and the light units were measured.
The normalized luciferase ratio was determined as NLR = [A17-C1/
A17-C2] / ([A17-C1/pSPICA-C2] + [A17-C2/pSPICA-C1]). Interactions
with a NLR above 3.5 are considered as speciﬁc interaction.
2.12. mRNA isolation and qRT-PCR analysis
Total RNA from exponential growth phase cell cultures of murine
ﬁbroblasts and HEK cells were isolated by using the GeneJET RNA
Puriﬁcation Kit (Thermo Scientiﬁc, Dreieich, Germany). Reverse
transcription was performed by using RevertAid Reverse Transcriptase
(Thermo Scientiﬁc, Dreieich, Germany) according to manufacturer's
instructions. Primers (ADAM17 primer left: 5′-AAG TGC AAG GCT GGG
AAA T-3′; ADAM17 primer right: 5′-CCT TGC ACG AGT TGT CAG TG-3′)
were designed by using Roche Universal ProbeLibrary Assay Design
Center and obtained from Euroﬁns MWG, Hamburg, Germany. The UPL-
Probe #109 was elected by using Roche Universal ProbeLibrary Assay
Design Center. All real-time PCR reactions were run in the LightCycler®
480 system (Roche, Basel, Switzerland) by using LightCycler® 480 Probes
Master (04887301001) according to manufacturer's instructions. Gene
expression levels were quantiﬁed using the LightCycler® 480 Software
1.5.0 (Roche, Basel, Switzerland). The relative expression levels of the
gene of interest were calculated by the 2−ΔΔCt method. Real-time PCR
experiments were performed in triplicates.
3. Results
3.1. Localization, trafﬁcking and maturation of ADAM17 lacking the
cytoplasmic portion
To address the function of the intracellular domain of murine
ADAM17 in terms of cellular localization and trafﬁcking we generated
a cytoplasmic portion-deﬁcient mutant termed ADAM17ΔCT, which
was truncated after cysteine 693 directly after the transmembrane
region [27] (Fig. 1A). We monitored localization and trafﬁcking of
ADAM17ΔCT in two distinct cell systems which strongly differ in their
expression levels: (i) transiently transfected ADAM17high-expressing
HEK cells and (ii) stably transfected ADAM17low-expressing murine
embryonic ﬁbroblast (mEF) isolated from ADAM17 knock-out or
hypomorphic mice. To determine ADAM17 expression levels in
transfected HEK and mEF cells, real-time PCR analysis of ADAM17
was conducted (Fig. 1B). Stable cDNA transfection increased ADAM17
mRNA expression by approximately 20 fold for ADAM17 and 2.5 fold
for ADAM17ΔCT in reconstituted ADAM17−/− ﬁbroblasts compared
to wt controls. Transiently transfected HEK cells displayed strong
upregulation of ADAM17 expression (~22,000 fold for ADAM17 and
700 fold for ADAM17ΔCT) as compared to mock transfected HEK cells
(Fig. 1B).
To ask whether ADAM17ΔCT translocates through the trans-Golgi
network to reach the cell surface, we performed ﬂow cytometry
experiments. ADAM17 cell surface expression was detectable in
both ADAM17 and ADAM17ΔCT overexpressing HEK cells indicating
that the cytoplasmic portion is dispensable for ADAM17 cell surface
translocation (Fig. 1C). These results were further corroborated by
live-cell activity assay. We directly quantiﬁed ADAM17 cell surface
activity by directly applying to the cell culture medium a soluble
ﬂuorogenic peptide containing the human TNFα cleavage site. The
peptide was time-dependently cleaved at 37 °C only by cell surface
localized ADAM17 as it did not penetrate the plasma membrane.ADAM17-overexpressing HEK cells showed measurable ADAM17
activity on the cell surface, which was not further enhanced after PMA
stimulation (Fig. 1D). We conclude that in ADAM17high-expressing
HEK cells, trafﬁcking of ADAM17was not affected in themutant lacking
the C-terminal portion as judged by ﬂow cytometry and life cell activity
assay. This notion was further strengthened by interaction studies
performed with the inactive rhomboid family member iRhom2, which
is an important regulator of ADAM17 trafﬁcking [32,33]. We transiently
co-transfected HEK cells with both, ADAM17 or ADAM17ΔCT cDNAs
and an N-terminal-ﬂag-tagged murine iRhom2 fusion protein and
performed co-immunoprecipitation experiments. As demonstrated in
Fig. 1E, the interaction betweenADAM17 and iRhom2was independent
of the intracellular domain since ADAM17 as well as ADAM17ΔCT co-
precipitated with iRhom2.
To characterize localization and cellular trafﬁcking of ADAM17ΔCT
in reconstituted ADAM17low-expressing mEF cells (ADAM17−/−
background) we used immunoﬂuorescence confocal microscopy. We
permeabilized cells prior to ﬁxation and staining with the ADAM17-
speciﬁc K133 antibody. Fig. 1F demonstrates the co-localization of
ADAM17 as well as ADAM17ΔCT with the KDEL receptor (ER marker).
Of note, we detected slightly more ER-resident ADAM17ΔCT than
ADAM17. No signiﬁcant co-localization with the cell surface marker
wheat germ agglutinin (WGA) was detectable in unstimulated
ADAM17−/−mEFs stably transfected with ADAM17 or ADAM17ΔCT
as also observed by others (Fig. 1G) [15,22]. In addition, neither
ADAM17 nor ADAM17ΔCT was detectable in signiﬁcant amounts
on the cell surface after stimulation with PMA or Anisomycin (Fig. 1G)
indicating that cell surface expressed ADAM17 and ADAM17ΔCT was
beyond our detection limit. Together, these data underline that under
physiological expression levels the bulk of ADAM17 and ADAM17ΔCT
resides in perinuclear vesicular compartments even after stimulation
with activating compounds like PMA or Anisomycin. This notion
was further strengthened by tracking ADAM17 and ADAM17ΔCT
maturation by endoglycosidase H (EndoH) and N-glycosidase F
(PNGaseF) treatment. We adsorbed glycoproteins by Concanavalin
A-Sepharose from transfected mEF cell lysates and treated the
precipitates with EndoH or PNGaseF (Supplemental Fig. 1). PNGaseF
removes all N-linked oligosaccharides whereas EndoH cleaves only
high mannose-type glycans added in the endoplasmic reticulum
(ER) but not complex-type oligosaccharides, which are processed
in the Golgi compartment [39]. As shown in Supplemental Fig. 1,
ADAM17 was detected as pro- and mature form migrating at 130 kDa
(red asterisk) and 110 kDa (blue asterisk), respectively (lane 1, upper
panel). Both forms shifted after EndoH treatment (lane 2, upper
panel). However only the mature form was further deglycosylated by
PNGaseF andmigrated as 80kDa protein (lane3, upper panel) indicating
that the former is localized in themedianGolgi. However, the proformof
ADAM17 displayed similar electrophoretic mobility after EndoH or
PNGaseF treatment, which is typical for ER- and proximal Golgi resident
proteins. Of note ADAM17ΔCT was detected only as unprocessed
proform (~110 kDa) (lane 4, upper panel). EndoH as well as PNGaseF
treatment resulted in one clear band of 90 kDa in ADAM17ΔCT lysates,
suggesting that the bulk of ADAM17ΔCT was located in the ER
and proximal Golgi (lanes 5 and 6, upper panel). Interestingly, PMA
treatment did not inﬂuence cellular distribution of ADAM17 or
ADAM17ΔCT as judged by EndoH or PNGaseF treatment (Supplemental
Fig. 1, lower panel). Based on our results we conclude that the C-terminal
tail of ADAM17 was not crucially involved in trafﬁcking through the
secretory pathway.
3.2. The cytoplasmic domain was not required for ADAM17 pre-dimer
formation in ADAM17 expressing HEK cells
Recently, it was suggested that ADAM17 activity is regulated
by homo-dimerization, and dimer formation was dependent on the
cytoplasmic portion [20]. We analyzed total lysates prepared from
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A1
7w
t
A1
7Δ
CT
D
AP
I
AD
AM
17
KD
EL
m
EF
A1
7-
/-  
TN
Fα
m
EF
A1
7-
/-  
TN
Fα
A1
7w
t
A1
7Δ
CT
enlarged enlarged
enlarged enlarged
1 2
3 4
5 6
1
2 3
54 6
enlargedAnisomycin
D
AP
I
AD
AM
17
W
G
A
B
CTTMSP PD CD DD MPD
ADAM17wt
ADAM17ΔCT
A
D
82
7
1 18 69
3
56
4
47
5
67
2
21
5
1
F
E
WB:α-flag
WB:α-ADAM17
IP:α-flag
WB:α-ADAM17
IP:α-flag
WB:α-flag
A1
7
A1
7+
iRh
om
2
A1
7Δ
CT
A1
7Δ
CT
+iR
ho
m2
100
130
100
130
100
130
100
G
0
5
10
15
20
25
600
700
800
20000
22500
25000
x-
fo
ld
AD
AM
17
ex
pr
es
si
on
mEF A17wt/wt
mEF A17-/-
mEF A17ex/ex- pQCXIH
mEF A17ex/ex- A17wt
mEF A17ex/ex- A17ΔCT
HEK
HEK-A17wt
HEK-A17 ΔCT
0
25
51
76
101
untransfected
A17wt
ADAM17
co
u
n
ts
105104103102-101-101-102 -102105104103102
0
25
51
76
101
untransfected
A17ΔCT
C
control
A17wt
A17ΔCT
control+PMA
A17wt+PMA
A17ΔCT+PMA
control+Ani
A17wt+Ani
A17ΔCT+Ani
control A17wt A17 Δ CT
0
5
10
15
20
25
R
FU
Flow cytometry of HEK cells
A17
Actin
30
25
20
15
10
5
-5
-10
0
control
PMA
Anisomycin
R
FU
10 20 30 40 50
Activity Assay of HEK cells
Real-time PCR
time [min]
AD
AM
17
wt
AD
AM
17
ΔC
T
m
EF
A1
7-
/-  
TN
Fα
m
EF
A1
7-
/-  
TN
Fα
m
EF
A1
7-
/-  
TN
Fα
Fig. 1. Trafﬁcking of ADAM17 lacking the cytoplasmic portion. A) Schematic overview of the murine ADAM17ΔCT mutant used in this study. The murine ADAM17ΔCT was truncated
directly after cysteine 693. SP, signal peptide; PD, prodomain; CD, catalytic domain; DD, disintegrin domain; MPD, membrane proximal domain; TM, transmembrane domain; CT,
cytoplasmic tail. B) mRNA levels of ADAM17 in stably transfected ﬁbroblasts and transiently transfected HEK cells were quantiﬁed by qRT-PCR and presented as relative fold changes
in reference to mock transfected parental cells. mGAPDH and hGAPDH were used as housekeeping genes. Data represent three in plate triplicates of three independent experiments.
C) Flow cytometry staining of ADAM17 on the cell surface of transiently transfected HEK cells overexpressing ADAM17 (left panel) or ADAM17ΔCT (middle panel). Parental mock
transfected cells served as negative control (gray peaks). All cell lines were treated with 10 μg/ml of the primary anti-ADAM17 (K133) antibody and subsequently with the secondary
Alexa488-labeled donkey anti-rabbit IgG. The right panel depicts a representativeWestern blot analysis of ADAM17 or ADAM17ΔCT transfected HEK cells. Actin served as loading control
D) Live cell ﬂuorescence activity assay: Relative surface activity of ADAM17 or ADAM17ΔCT in transfected HEK cells was determined using the ﬂuorogenic peptide MCA-PLAQAV(Dpa)
RSSSR-NH2 in the presence or absence of PMA (200 nM) or Anisomycin (2 μM). Proteolytic activity was calculated relative to the emission at 405 nm with an excitation at 320 nm. In
the upper panel the cleavage kinetic was followed over a period of 50 min and demonstrated linear increase. The lower panel represents the Relative ﬂuorescence units (RFU) after
50 min. Data depict a representative kinetic of at least three independent experiments (two in plate duplicates ± SD). Baseline indicates background peptide turnover after 50 min.
E) ADAM17 or ADAM17ΔCT was transiently co-transfected with iRhom2-ﬂag in HEK cells, and iRhom2was precipitated using an anti-ﬂag (M2) antibody. Co-precipitation was analyzed
by SDS-PAGE andWestern blotting using the polyclonal anti-ADAM17 (10.1) antibody. Single transfections of ADAM17 or ADAM17ΔCT served as speciﬁcity controls. Expression levels of
ADAM17, ADAM17ΔCT and iRhom2 were monitored by Western blotting in the lysates with anti-ﬂag (M2) and anti-ADAM17 (10.1). F–G) Subcellular localization of ADAM17 or
ADAM17ΔCT in transfected ADAM17−/−mEFs in the presence or absence of PMA (200 nM) or Anisomycin (2 μM). Cells were ﬁxed, permeabilized and immunostained with antibodies
against ADAM17 (K133-Alexa488) and either KDEL receptor (Alexa594) (D) or WGA-rhodamin (G).
3359J. Schwarz et al. / Biochimica et Biophysica Acta 1833 (2013) 3355–3367ADAM17 and ADAM17ΔCT expressing HEK cells under non-reducing
and reducing conditions by Western blotting (Fig. 2A). The blots when
probed with the α-ADAM17 (10.1) antibody revealed the presence ofSDS-stable higher order multimers with an apparent molecular weight
of ~350 kDa in addition to the monomeric ADAM17 form [~130 kDa].
However, reduction of the samples with DTT or β-mercaptoethanol
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ADAM17 (10.1) antibody. B) 0.2 × 106 NIH3T3 cells were transiently co-transfected with cDNAs encoding ADAM17-C1 and ADAM17-C2 as well as ADAM17ΔCT-C1 and ADAM17ΔCT-
C2 split-luciferase fusion proteins. Mock transfected cells served as negative controls. Cells were lysed two days after transfection and luciferase activity wasmeasured by Coelenterazine
conversion. Normalized luciferase ratios were calculated as described inMaterials andmethods. C) 1×106 HEK cells were transiently transfected as described above. After 24h cells were
equally split into 3 wells and stimulated with vehicle (DMSO), PMA (200nM) or Anisomycin (2 μM) for 2 h. Cells were lysed and luciferase activity was measured. Lysates were used for
immunoblotting against ADAM17. Data in (B) and (C) are representative of experiments performed at least four times, and are shown as average± S.D. of triplicates.
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shown in Fig. 2A we detected SDS-stable higher molecular weight
bands also in ADAM17ΔCT expressing HEK cells. To analyze the
involvement of the transmembrane region of ADAM17 we analyzed
homomultimerization of an ADAM17-GPI fusion protein consisting
of ADAM17 ectodomain (amino acids 1–670) linked to the GPI signal
of TRAIL. As shown in Fig. 2A, upon SDS-PAGE, ADAM17-GPI appears
as monomers [~110 kDa] and multimers [~300 kDa], indicating that
ADAM17 multimerization is mediated neither by the cytoplasmic
tail nor by the transmembrane domain. Of note, theα-actin antibody
used throughout this study failed to visualize actin in the unreduced
samples.
To further address the multimerization state of ADAM17 and
ADAM17ΔCT we used a protein-interaction-detection assay relying on
complementation of split Gaussia princeps luciferase [38]. In this assay
the N(C1)- and C(C2)-terminal fragments of luciferase were fused
C-terminally to ADAM17 or ADAM17ΔCT, respectively (Supplemental
Fig. 2A). Co-transfection of ADAM17-C1 and ADAM17-C2 resulted in
strong induction of luminescence supporting previous ﬁndings that
ADAM17 forms homodimers. As a negative control, we co-expressed
the non-interacting pair ADAM17-C1 and CyclophilinA-C2 or ADAM17-
C2 and CyclophilinA-C1 to determine levels of background luminescence.
In these cases, no luciferase activitywas observed (Supplemental Fig. 2B).
Interestingly, ADAM17ΔCT was also able to form homodimers in
NIH3T3 and HEK cells (Fig. 2B, C). In addition, we determined whether
ADAM17 activation by PMA or Anisomycin inﬂuenced the abundance
of ADAM17 dimers (Fig. 2C). To this end, we co-transfected HEK cells
with ADAM17-C1 and ADAM17-C2 as well as ADAM17ΔCT-C1 and
ADAM17ΔCT-C2 and stimulated for 1 h with PMA or Anisomycin. By
immunoblotting with anti-phospho-ERK and anti-phospho-p38 MAPK
antibodies we visualized the activation of ERK and p38 MAPK after
PMA and Anisomycin treatment. Whereas phosphorylated ERK was
only detectable after PMA stimulation, phosphorylated p38-MAPK was
present in both, PMA and Anisomycin treated HEK cells (Supplemental
Fig. 2C).We assessed the dimerization state of ADAM17 andADAM17ΔCT
before and after PMA or Anisomycin stimulation by quantiﬁcation of
the luciferase activity. PMA led to a slight but not signiﬁcant increase
of ADAM17 dimer formation in ADAM17-C1 and ADAM17-C2 as well
as ADAM17ΔCT-C1 and ADAM17ΔCT-C2 double transfected HEK
cells. Anisomycin treatment slightly promoted dimer formation inADAM17ΔCT-C1 and ADAM17ΔCT-C2 double transfected HEK cells.
Therefore, we conclude that in our experimental system, ADAM17
dimer formation did not require the cytoplasmic portion of the
protein.
3.3. Complete truncation of the cytoplasmic domain of ADAM17 resulted in
loss of pro-TNFα shedding
To address whether ADAM17ΔCT can still cleave its substrates, we
generated stable double-transfected ADAM17ex/ex mEFs, expressing
equal amounts of both pro-TNFα togetherwith ADAM17 or ADAM17ΔCT
(Fig. 3A, B). Pro-TNFαmigrated through SDS-PAGE as two forms with an
apparent size of 25 kDa and 32 kDa, which probably represent two
distinct glycosylation forms of the full-length precursor [40] (Fig. 3A).
Recently, we described an unexpected species speciﬁcity of ADAM17
related to its substrate IL-6R [41]. To avoid any species speciﬁcity effects
we used murine pro-TNFα cDNA for the transduction of wt as well
as ADAM17ex/ex mEFs although we could also show that murine
ADAM17 shed murine as well as human TNFα after PMA stimulation
(Supplemental Fig. 3A). We monitored the shedding activity after
PMA stimulation by ELISA (Fig. 3C). The shed TNFα levels were
measured in cell supernatants of ADAM17ex/ex (negative control), wt
(positive control) as well as reconstituted ADAM17ex/ex mEFs. Only
the wt mEFs and the ADAM17ex/ex mEFs reconstituted with ADAM17
cDNA showed a time-dependent increase of TNFα-levels in the cell
supernatant. ADAM17ex/ex mEFs showed impaired TNFα shedding.
Surprisingly, also ADAM17ΔCT expressing cells displayed strongly
impaired TNFα-shedding after PMA-stimulation, although, the same
mutant processed the ﬂuorogenic peptide containing the TNFα cleavage
site (Fig. 3C, and 1D). Thus, ADAM17ΔCT had the catalytic properties to
enzymatically cleave artiﬁcial substrates but was incapable to associate
with the physiological membrane-bound pro-TNFα. Importantly, wt
mEFs as well as the ADAM17ex/ex reconstituted with ADAM17 cDNA
showed similar TNFα shedding activity. Both, ADAM17ex/ex and mEFs
reconstituted with ADAM17ΔCT displayed strongly impaired shedding
of TNFα after PMA-stimulation (Fig. 3C). These results were validated
by ﬂow cytometry staining of TNFα on the cell surface. Treatment with
Cycloheximide (CHX) 1 h prior PMA stimulation resulted in time-
dependent chase of the newly synthesized pro-TNFα on the cell surface.
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3361J. Schwarz et al. / Biochimica et Biophysica Acta 1833 (2013) 3355–3367TNFα cell surface expression after PMA treatment in contrast to
ADAM17ex/ex mEF cells, which were reconstituted with ADAM17ΔCT
(Fig. 3D). These data demonstrate that in ADAM17 deﬁcient mEFs,
the ADAM17ΔCT mutant lacking the complete cytoplasmic domain
is not activated after PMA stimulation.
3.4. The majority of the cytoplasmic domain of ADAM17 was not essential
for the shedding activity
As the ADAM17ΔCT mutant displayed a similar trafﬁcking pattern
but a complete loss of shedding activity as compared to ADAM17, we
wanted to identify the minimal cytoplasmic part necessary for the
restoration of shedding by generating further truncations of ADAM17
(Fig. 4A). The ADAM17Δ700 mutant contained the ﬁrst six amino
acids of the ADAM17 cytoplasmic tail and was truncated directly
upstream of the ﬁrst potential phosphorylation site (tyrosine 712).
The ADAM17Δ735 mutant was truncated directly after glutamine
734 and lacks the phosphorylation site threonine 735. It was shown in
previous studies that phosphorylation of threonine 735 after p38 and
ERK activation induced trafﬁcking of ADAM17 to the cell surface [22].
These ADAM17 mutants were stably co-transfected together with the
substrate pro-TNFα in hypomorphic ADAM17ex/ex mEFs (Fig. 4B).
We assessed ADAM17 enzymatic activity in all transfected cell lines
by monitoring pro-TNFα cleavage (Fig. 4C). We observed a signiﬁcant
increase of soluble TNFα after PMA stimulation in the supernatants
of ADAM17, ADAM17Δ700 and ADAM17Δ735 expressing ﬁbroblasts.As depicted in Fig. 4C, control as well as ADAM17ΔCT expressing
cells displayed no pro-TNFα shedding activity. Remarkably, the
ADAM17Δ700 mutant, which differs from ADAM17ΔCT only in the
short charged 6 amino acid long stretch N-VDKKLD-C displayed full
activity after PMA stimulation as judged by pro-TNFα shedding. In
addition, we applied the widely used hydroxamate based inhibitors
GI254023X (ADAM10 inhibitor) and GW208264 (combined ADAM10
and ADAM17 inhibitor) during PMA stimulation (Supplemental Fig. 3B)
[42,43]. PMA induced shedding was blocked by GW208264 but not by
GI254023X, corroborating its dependence on ADAM17 (Supplemental
Fig. 3B). The same experiments were conducted with Anisomycin
stimulation. Anisomycin-induced shedding led to an approximate 1.5-
fold increase of TNFα in supernatants of ADAM17 and ADAM17Δ700
reconstitutedmEFs,whichwas also blocked byGW208264. As observed
after PMA treatment, ADAM17ΔCT expressing cells displayed no pro-
TNFα shedding activity after Anisomycin stimulation (Supplemental
Fig. 3B).
It was previously described that application of the phosphatase
inhibitors Cantharidin or Calyculin A led to phosphorylation and
strong activation of ADAM17 mediated L-selectin shedding [17].
We therefore treated ADAM17, ADAM17Δ700 and ADAM17ΔCT
reconstituted ADAM17ex/ex mEF cells with 40 nM Calyculin A or
500 μM Cantharidin. Calyculin A as well as Cantharidin induced
TNFα shedding indicating that phosphatase inhibition led to global
ADAM17 activation and was not conﬁned to the induction of L-selectin
cleavage. Interestingly, Calyculin A and Cantharidin-induced shedding
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3362 J. Schwarz et al. / Biochimica et Biophysica Acta 1833 (2013) 3355–3367was blocked by GI254023X as well as GW208264 in control as well
as ADAM17ΔCT expressing cells. In contrast, only GW208264 inhibited
the Calyculin A and Cantharidin-induced shedding in ADAM17 and
ADAM17Δ700 expressing ﬁbroblasts (Fig. 4D, E). As already observed
by Le Gall and co-workers [25], these data indicate that in case of lacking
ADAM17 activity, the close relative ADAM10, which is inhibited
efﬁciently by GI254023X compensated the loss of TNFα shedding after
Calyculin A and Cantharidin stimulation. However, as small molecular
inhibitors like GI254023X might also interfere with the activity of other
proteases, further experiments in ADAM10-deﬁcient ﬁbroblasts will be
necessary to prove that Calyculin A and Cantharidin-induced pro-TNFαshedding is compensated by ADAM10 in the absence of ADAM17.
Further, the ADAM17Δ700 mutant was able to rescue the loss of
Calyculin A and Cantharidin-induced shedding in ADAM17ex/ex mEFs.
Finally, we tested constitutive as well as stimulated shedding of the
endogenously expressed ADAM17 substrates TNFRI and TNFRII. We
conditioned the cell culture media for up to 4 h with the inhibitors
GW208264 or GI254023X. Again, except for ADAM17ΔCT expressing
cells, all stably transfected ADAM17ex/ex mEF cell lines showed
constitutive shedding of TNFRI and TNFRII, which was blocked only
by the combined ADAM17 and ADAM10 inhibitor GW208264 but
not by the ADAM10 inhibitor GI254023X (Fig. 4F, G). Further, the
3363J. Schwarz et al. / Biochimica et Biophysica Acta 1833 (2013) 3355–3367minimal shedding activity, which was measured in ADAM17ΔCT
expressing ﬁbroblasts was completely blocked by the ADAM10
inhibitor GI254023X, indicating again a compensatory mechanism
in the absence of functional ADAM17 (Fig. 4F). Moreover PMA,
Anisomycin, Calyculin A aswell as Cantharidin-induced TNFRI shedding
was abolished in ADAM17ΔCT expressing cells and was rescued by
expression of ADAM17 or ADAM17Δ700 (Fig. 4H, I). From these
experiments we conclude that ADAM17 mediated TNFα, TNFRI and
TNFRII shedding is completely independent of the phosphorylation
at T735 within the cytoplasmic portion of ADAM17. However, the
membrane-proximal charged sequence stretch N-VDKKLD-C is essential
for ADAM17 activity.
3.5. Impaired prodomain processing was not the cause of lost ADAM17ΔCT
enzymatic activity
The ADAM17Δ700 mutant retained full enzymatic activity as
compared to ADAM17ΔCT. By SDS-PAGE we detected only one
immunoreactive band of ADAM17ΔCT, which migrated at 110 kDa
and corresponded to the variant still containing the prodomain
(Supplemental Fig. 1A). Therefore, we hypothesized that lack of
prodomain removal was the cause of the enzymatic inactivity towards
pro-TNFα, which we monitored in ADAM17ΔCT expressing cells. By
using recombinant ADAM17 it was previously demonstrated that furin
recognizes the RVKR sequence located C-terminal to arginine-210 at
the boundary between the pro- and the catalytic domain of ADAM17
[30]. We immunoprecipitated ADAM17 and ADAM17ΔCT from stably
transfected ADAM17ex/ex mEF cells and incubated the precipitated
proteins with recombinant furin. The ADAM17 fragments were
visualized by Western blotting as bands of 130 kDa (pro) and 110 kDa
(mature) for ADAM17 and 110 kDa (pro-form) and 90 kDa (mature)
for ADAM17ΔCT. Importantly, the mature form of ADAM17ΔCT was
detected in the sample to which recombinant furin was added
(Fig. 5A). Thus, we conclude that the furin cleavage-site is not masked
in the ADAM17ΔCT mutant by conformational hindrance.
To assesswhether prodomain removal of ADAM17 is required for its
constitutive or stimulated activity, we generated mutants, in which the
furin cleavage site RVKRwasmutated to RVNG (ADAM17RVNG) or AGAG
(ADAM17AGAG). We stably transfected both furin-resistant ADAM17
mutants in pro-TNFα expressing ADAM17ex/ex mEFs (Fig. 5B) and
also in HEK cells. Next, we assessed their cell surface expression by
ﬂow cytometry analysis (Fig. 5C). Both mutants, ADAM17RVNG and
ADAM17AGAG were expressed on the cell surface although to a
slightly lesser extent as compared to wt ADAM17. To conﬁrm the
furin-resistance we immunoprecipitated ADAM17, ADAM17RVNG
and ADAM17AGAG from stably transfected ADAM17ex/ex mEF cells and
incubated the precipitated proteins with recombinant furin. ADAM17
was visualized by Western blot analysis primarily in its immature
proform (130 kDa) and in a weak second band (~120 kDa) probably
corresponding to a differentially glycosylated form. After furin incubation
both ADAM17 bands displayed an approximately 20 kDa SDS-PAGE
gel-shift, which corresponds to the apparent molecular weight of the
prodomain. In contrast to ADAM17, the ADAM17RVNG and ADAM17AGAG
mutants were resistant to furin cleavage conﬁrming the canonical furin-
like cleavage site RVKR at the boundary between the prodomain and
the catalytic domain of ADAM17 (Fig. 5D).
Next we monitored PMA, lysophosphatidic acid (LPA) and Calyculin
A induced shedding activity of the ADAM17RVNG and ADAM17AGAG
mutants. Surprisingly, expression of both furin-resistantmutants rescued
TNFα shedding in hypomorphic ADAM17ex/ex mEFs. As shown in Fig. 5E,
a 3-fold increase of TNFα shedding in ADAM17 reconstituted ﬁbroblasts
after stimulation with PMA was observed. PMA stimulation led to a
2-fold increase in TNFα shedding in ADAM17RVNG and ADAM17AGAG
reconstituted ﬁbroblasts. Further, we detected a 1.5-fold increase of
TNFα shedding after stimulation with the G-protein coupled receptor
agonist LPA and the phosphatase inhibitor Calyculin A (Fig. 5F). Thesame stimulation led to a 2-fold increase in TNFα shedding in
ADAM17RVNG and ADAM17AGAG reconstituted ﬁbroblasts.
From these results we conclude that furin or furin-like activity was
not essential for stimulated ADAM17 activity in our experimental
conditions. Thus, other as yet unknown biochemical properties led to
the enzymatic inactivity of the ADAM17ΔCT constructs in terms of
pro-TNFα cleavage.
3.6. The cytoplasmic portion of TNFα was dispensable for
ADAM17-mediated proteolytic cleavage
As ADAM17Δ700 was fully activated after stimulation with the
compounds PMA, Anisomycin, Cantharidin and Calyculin A, which all
trigger phosphorylation and activation of intracellular serine/threonine
kinases. However, to date it has not been investigated whether the
activation of ERK or p38-MAPK targets the cytoplasmic portion of the
substrates TNFα. The cytoplasmic portion of murine TNFα consists of
29 amino acids and harbors 2 potential phosphorylation sites (serine-
5 and serine-27). To address the question if the intracellular domain
of TNFα is important for proteolytic cleavage, we generated a murine
ﬂag-tagged TNFα mutant lacking the complete cytoplasmic portion.
The TNFαΔNTﬂag mutant was expressed and translocated to the
plasma membrane in transiently transfected HeLa cells as judged by
confocal imaging (Fig. 6A). Next, we transiently transfected HEK as
well as HepG2 cells with TNFαwtﬂag or TNFαΔNTﬂag and measured
the release of the ectodomain in the conditionedmedia after stimulation.
In addition, the lysateswere subjected toWesternblotting andprobed for
TNFαwtﬂag or TNFαΔNTﬂag expression using an anti-ﬂag antibody
(Fig. 6B). As shown in Fig. 6C and D, stimulation of HEK or HepG2
cells with PMA, Anisomycin and Calyculin A led to increased TNFαwt
shedding. Further, deletion of the N-terminal portion did not impair but
rather enhanced the proteolytic release of TNFα. Thus, we conclude
that the cytoplasmic portion is dispensable for the proteolytic release of
TNFα after triggering ADAM17 activation.
4. Discussion
The function of ADAM17 is crucial for the regulation of inﬂammatory
responses. Among the numerous ADAM17 substrates, membrane-
tethered pro-TNFα and both its receptor subunits TNFRI and TNFRII
demonstrate the importance of ectodomain shedding in controlling
inﬂammatory signaling pathways [14,44]. ADAM17 activates TNFα
signaling by proteolytic cleavage of pro-TNFα thereby releasing the
active cytokine from the cell surface. Moreover, ADAM17 can also
attenuate TNF-signaling by releasing the antagonistic soluble TNFRs
which retain the ability to bind TNFα and block receptor engagement
and subsequent signaling [45]. The example of TNF signaling shows
that ADAM17 governs the balance between pro- and anti-inﬂammatory
pathways, thereby controlling the appropriate responses of the body to
damage and stress [14]. Interestingly, MAPK-induced signaling cascades
are activated during inﬂammatory responses like sepsis, infection and
arthritis correlating with enhanced ADAM17 activity [46,47] and further,
direct phosphorylation of ADAM17 is believed to enhance ectodomain
shedding of various substrates thereby enabling inside-out signaling
[16–22]. However, neither PKCα nor p38-MAPK knock-out mice
phenocopy ADAM17-deﬁcient mice, which are embryonically lethal
probably due to misshaped heart valves [10,48,49].
In our study, we aimed to deﬁne the function of the 133 amino
acid long ADAM17 cytoplasmic tail in terms of cellular localization,
dimerization and activation especially after stimulation of intracellular
PKC and MAPK pathways. We employed two cell culture models,
which enabled us functional analysis of ADAM17 mutants lacking the
cytoplasmic portion in ADAM17high-expressing HEK and ADAM17low-
expressing mEF cells.
Previous reports highlight that cytoplasmic phosphorylation of
ADAM17 controls secretory trafﬁcking to the cell surface. For the related
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by Western blotting using the ADAM17 (10.1) antibody. C) Flow cytometry staining of ADAM17 on the cell surface of transiently transfected HEK cells overexpressing ADAM17,
ADAM17RVNG or ADAM17AGAG. Parental mock transfected cells served as negative control (light gray bar). All cell lines were treated with 10 μg/ml of the primary anti-ADAM17 (K133)
antibody and subsequently with the secondary Alexa488-labeled donkey anti-rabbit IgG. Columns represent mean ﬂuorescence intensity of three independent experiments. D) Furin
cleavage assay with either ADAM17, ADAM17AGAG or ADAM17RVNG reconstituted ADAM17ex/ex mEFs was performed and analyzed as described in A. E) Indicated cell lines were seeded
at a density of 2×105 cells and stimulated for 2hwith PMA (200nM) in the presence or absence of themetalloprotease inhibitors GI orGW. Cells were pretreatedwith the inhibitor GI and
GW (3 μM) 10min prior to stimulation. Secreted TNFαwasmeasured by ELISA in the cell-free supernatants. F) Indicated cell lines were seeded at a density of 2×105 cells and stimulated
for 30minwith the phosphatase inhibitor Calyculin A (40nM), or the G-protein coupled receptor agonist LPA (10μM). Secreted TNFαwasmeasured by ELISA in the cell-free supernatants.
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is mediated by an arginine rich-motif located within the ADAM10
intracellular tail [50] and moreover the cytoplasmic domain of ADAM12
as well as of ADAM22 regulates ER-export [51,52]. In this study, we
used ﬂow cytometry and immunocytochemistry to compare cellular
trafﬁcking of wt ADAM17 and ADAM17ΔCT, a mutant, which was
truncated after cysteine-693 of murine ADAM17 [27]. ADAM17 and
ADAM17ΔCT were localized in perinuclear vesicular compartments
andwere not transported to the cell surface after PMA or Anisomycin
treatment in stably transfected mEF cells. These results are in good
agreement with previous studies demonstrating that ADAM17 resided
in the ER [15,53]. Further, ADAM17ΔCT co-immunoprecipitated withiRhom2, which is an important regulator of ADAM17 trafﬁcking
from the ER to the trans-Golgi network in macrophages [32,33].
Two hypotheses might explain these ﬁndings: (i) Cell surface expression
of ADAM17 strongly depends on the cell type as some cellsmight express
ADAM17-binding partners, which guide the protease to the cell
surface where it encounters the substrates; and/or (ii) transcriptional
upregulation of ADAM17 above a certain threshold level leads to cell
surface translocation because excess ADAM17 escapes ER retention
and translocates through the trans-Golgi network to the cell surface.
As several studies have shown that tumor tissues and tumor cell lines
produce signiﬁcantly more ADAM17 mRNA [54,55] and express high
levels of ADAM17 at the cell surface [56,57], we tend to the second
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C) 1×106 HEK cells transiently transfectedwith low amounts (0.5μg) of TNFαwt or TNFαΔNT encoding plasmids. TNFα sheddingwas stimulated by PMA (200nM), Anisomycin (2μM)or
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mEF cells isolated fromADAM17-overexpressing transgenicmice showed
increased ADAM17 cell surface levels compared towt cells [58]. From our
experiments, we propose that strong transcriptional upregulation of
ADAM17 led to cell surface translocation of even immature ADAM17
underlined by cell surface localization of ADAM17ΔCT as well as the
furin-resistant mutants ADAM17AGAG and ADAM17RVNG. However,
comparable to ADAM17low-expressing mEF cells subcellular localization
of ADAM17 was not inﬂuenced by PMA or Anisomycin stimulation in
ADAM17high-expressing HEK.
In a recent study it has been suggested that the cytoplasmic
portion of ADAM17 and ADAM10 is crucial for dimerization. ADAM17
homodimers were detected on the cell surface where they interact
with the natural ADAM17-inhibitor TIMP3. Moreover, threonine 735
(T735) phosphorylation of ADAM17 suppressed dimerization thereby
releasing TIMP3, which led to ADAM17 activation [20]. In our study,
we addressed the putative function of ADAM17-ICD inmultimerization.
We overexpressed ADAM17 and ADAM17ΔCT in HEK cells and
demonstrated that a sub-fraction of ADAM17 and ADAM17ΔCT forms
SDS-stable multimers under non-reducing conditions. Moreover,
ADAM17 dimer formation was not affected by activation of p38 and
ERK kinase activation by PMA or Anisomycin in our experimental
setting. Further, we studied ectodomain multimer formation by
expressing the extracellular domain of ADAM17 linked to a glyco-
phosphatidyl (GPI) anchor and found that ADAM17 multimerized
in the absence of a transmembrane domain. Besides other proposedmechanisms for ADAM17 multimerization [20], we believe that inter-
molecular disulﬁde linkage between cysteines in the extracellular portion
of ADAM17 might be involved in clustering of ADAM17. Accordingly,
a previous study demonstrated that ADAM17 multimerization was
mediated by the extracellular portion and in particular by themembrane
proximal EGF-like domain [59]. In addition it was shown that ADAM17
activation depends on rapid conformational changes through intra-
molecular disulﬁde bond isomerization within the extracellular portion
[25,60–62]. It will be interesting to investigate if intermolecular disulﬁde
bond formation between two ADAM17 molecules is also involved in
the regulation of ectodomain shedding. Future studies will reveal if
monomer–dimer equilibrium of ADAM17 molecules interferes with
substrate recognition or activation for example by disruption of the
dimer interface in the ADAM17 extracellular domain.
The impact of phosphorylation in regulating ADAM17 activity is
still a matter of debate. Direct phosphorylation is supposed to be a
molecular hallmark of ADAM17 activation. To address the function
of the intracellular domain of murine ADAM17 in terms of cellular
trafﬁcking we generated two cytoplasmic portion-deﬁcient mutants
termed (i) ADAM17ΔCT, which was based on a construct, which has
been used in a previous study and was truncated directly after
cysteine 693 and (ii) ADAM17Δ700 containing the ﬁrst six amino
acids of the natural ADAM17 cytoplasmic tail and was truncated
after aspartate 699 [25,27]. As epitope tags can interfere with protein
function we analyzed shedding activity with untagged versions of
these mutants.
3366 J. Schwarz et al. / Biochimica et Biophysica Acta 1833 (2013) 3355–3367Our data are in agreement with previous studies showing that
activation of ADAM17 by several stimuli was completely independent
of cytoplasmic phosphorylation [24,25,27,31,63,64]. Moreover, the
ADAM17Δ700 mutant lacking all phosphorylation sites also rescued
Calyculin A and Cantharidin-induced TNFα shedding indicating that
inhibition of serine/threonine phosphatases and subsequent intracellular
activation of serine/threonine kinases led to activation of ADAM17 by a
molecular mechanism independent of the proposed inside-out signaling
pathway involving direct ADAM17 phosphorylation. However, further
deletion of the charged sequence stretch N-VDKKLD-C led to complete
inactivation of ADAM17 demonstrating that the charge balance around
the transmembrane domain could be crucial for proteolytic activity. In
particular, it was demonstrated for ADAM17 that the transmembrane
domain itself regulates shedding activity for some, but not all
substrates [25,31,65]. Further, rapid changes of the lipid composition
by Methyl-β-cyclodextrin-induced cholesterol depletion or apoptosis-
mediated phosphatidylserine externalization led to rapid ADAM17
activation [66,67]. Therefore we hypothesize that the juxtamembrane
intracellular sequence either anchored ADAM17 in the correct lipid
bilayer microenvironment or stabilized the TM domain. Along this line
of speculation, some charged epitope tags used in previous studies
mightmimic the natural ADAM17 juxtamembrane sequence and restore
ADAM17ΔCT proteolytic activity. Thus, the controversial experimental
results regarding the enzymatic activity of ADAM17 mutants lacking
the cytoplasmic portion might be evoked by (i) design of the mutants
and (ii) the C-terminal epitope tag.
Interestingly, ADAM17ΔCT was not converted into the mature
form devoid of the prodomain. However, our experiments with furin-
resistant mutants demonstrate that impaired prodomain removal was
not the reason for the enzymatic inactivity of ADAM17ΔCT as both
mutants responded to various stimuli such as PMA, Calyculin A and
activation of G-protein coupled receptors by lysophosphatidic acid. It
was already shown that the canonical ‘cysteine switch’ mechanism
responsible for keeping matrix metalloproteases in an inactive state
does not apply for ADAM17 [68] and that PMA-induced shedding was
not impaired in presence of the cell permeable furin inhibitor RVKR-
fmk, which suppressed furin-dependent prodomain cleavage [25].
However, although prodomain removal was not essential for ADAM17
activation in our experiments, it might play an important role in
other ADAM17 activation pathways, which were not addressed in
this study. Moreover, a recent degradome analysis revealed that besides
furin themetalloproteasemeprin β is involved in propeptide cleavage of
ADAM10 [69]. It will be interesting to investigate if furin-independent
proteolytic release of the prodomain also occurs in ADAM17.
5. Conclusions
This study demonstrates that deletion of the complete C-terminal
portion of ADAM17 abolished proteolytic activity of the enzyme
without affecting subcellular localization, iRhom2 interaction or
dimerization. The enzymatic activity of ADAM17ΔCT was restored
by expanding the C-terminal portion by only 6 amino acids. Although
phosphorylation of either the ADAM17 or TNFα cytoplasmic portion
seems not to have regulatory functions in vitro we cannot exclude
that cytosolic phosphorylation regulates ADAM17 activity in vivo. To
date, there is poor understanding, which pathways regulate ADAM17-
mediated ectodomain shedding in the body. Therefore, the generation
of ADAM17ΔCT transgenic knock-in mice might represent a valuable
tool for further studies on ADAM17 regulation.
Acknowledgements
We thank Melanie Boss, Dana Dohr and Kaja Köhler for excellent
technical assistance; Dr. Paul Saftig and Dr. Karina Reiss for the
ADAM17 deﬁcient (ADAM17−/−) mEF cells; Dr. Bernd Schröder for
providing the polyclonal anti-TNFα antibody; Dr. Inken Lorenzen fordiscussion and advice; Dr. Yves Jacob for providing the Split-Luciferase
expression plasmids, Sonderforschungsbereich 877 (project Z3) for
providing antibodies; and Sonderforschungsbereich 877 (project Z2)
for providing excellent technical assistance.
Appendix A. Supplementary data
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbamcr.2013.10.005.
References
[1] C.P. Blobel, ADAMs: key components in EGFR signalling and development, Nat. Rev.
Mol. Cell Biol. 6 (2005) 32–43.
[2] K. Reiss, P. Saftig, The “A Disintegrin And Metalloprotease” (ADAM) family of
sheddases: physiological and cellular functions, Semin. Cell Dev. Biol. 20 (2009)
126–137.
[3] P. Saftig, K. Reiss, The “A Disintegrin And Metalloproteases” ADAM10 and ADAM17:
novel drug targets with therapeutic potential? Eur. J. Cell Biol. 90 (2011) 527–535.
[4] M. Gooz, ADAM-17: the enzyme that does it all, Crit. Rev. Biochem. Mol. Biol. 45
(2010) 146–169.
[5] S. Rivera, M. Khrestchatisky, L. Kaczmarek, G.A. Rosenberg, D.M. Jaworski, Metzincin
proteases and their inhibitors: foes or friends in nervous system physiology?
J. Neurosci. 30 (2010) 15337–15357.
[6] R.A. Black, C.T. Rauch, C.J. Kozlosky, J.J. Peschon, J.L. Slack, M.F.Wolfson, B.J. Castner, K.L.
Stocking, P. Reddy, S. Srinivasan, N. Nelson, N. Boiani, K.A. Schooley, M. Gerhart, R.
Davis, J.N. Fitzner, R.S. Johnson, R.J. Paxton, C.J.March, D.P. Cerretti, Ametalloproteinase
disintegrin that releases tumour-necrosis factor-alpha from cells, Nature 385 (1997)
729–733.
[7] M.L. Moss, S.L. Jin, M.E. Milla, D.M. Bickett, W. Burkhart, H.L. Carter, W.J. Chen, W.C.
Clay, J.R. Didsbury, D. Hassler, C.R. Hoffman, T.A. Kost, M.H. Lambert, M.A. Leesnitzer,
P. McCauley, G. McGeehan, J. Mitchell, M. Moyer, G. Pahel, W. Rocque, L.K. Overton,
F. Schoenen, T. Seaton, J.L. Su, J.D. Becherer, et al., Cloning of a disintegrin
metalloproteinase that processes precursor tumour-necrosis factor-alpha, Nature
385 (1997) 733–736.
[8] K. Horiuchi, T. Kimura, T. Miyamoto, H. Takaishi, Y. Okada, Y. Toyama, C.P. Blobel,
Cutting edge: TNF-alpha-converting enzyme (TACE/ADAM17) inactivation in
mouse myeloid cells prevents lethality from endotoxin shock, J. Immunol. 179
(2007) 2686–2689.
[9] C. Long, Y. Wang, A.H. Herrera, K. Horiuchi, B. Walcheck, In vivo role of leukocyte
ADAM17 in the inﬂammatory and host responses during E. coli-mediated
peritonitis, J. Leukoc. Biol. 87 (2010) 1097–1101.
[10] J.J. Peschon, J.L. Slack, P. Reddy, K.L. Stocking, S.W. Sunnarborg, D.C. Lee, W.E. Russell,
B.J. Castner, R.S. Johnson, J.N. Fitzner, R.W. Boyce, N. Nelson, C.J. Kozlosky, M.F.
Wolfson, C.T. Rauch, D.P. Cerretti, R.J. Paxton, C.J. March, R.A. Black, An essential
role for ectodomain shedding in mammalian development, Science 282 (1998)
1281–1284.
[11] K. Brandl, L. Sun, C. Neppl, O.M. Siggs, S.M. Le Gall, W. Tomisato, X. Li, X. Du, D.N.
Maennel, C.P. Blobel, B. Beutler, MyD88 signaling in nonhematopoietic cells protects
mice against induced colitis by regulating speciﬁc EGF receptor ligands, Proc. Natl.
Acad. Sci. U. S. A. 107 (2010) 19967–19972.
[12] K. Brandl, W. Tomisato, B. Beutler, Inﬂammatory bowel disease and ADAM17
deletion, N. Engl. J. Med. 366 (2012) 190(author reply 190).
[13] A. Chalaris, N. Adam, C. Sina, P. Rosenstiel, J. Lehmann-Koch, P. Schirmacher, D.
Hartmann, J. Cichy, O. Gavrilova, S. Schreiber, T. Jostock, V. Matthews, R. Hasler, C.
Becker, M.F. Neurath, K. Reiss, P. Saftig, J. Scheller, S. Rose-John, Critical role of the
disintegrin metalloprotease ADAM17 for intestinal inﬂammation and regeneration
in mice, J. Exp. Med. 207 (2010) 1617–1624.
[14] J. Scheller, A. Chalaris, C. Garbers, S. Rose-John, ADAM17: a molecular switch to
control inﬂammation and tissue regeneration, Trends Immunol. 32 (2011) 380–387.
[15] J. Schlondorff, J.D. Becherer, C.P. Blobel, Intracellular maturation and localization of
the tumour necrosis factor alpha convertase (TACE), Biochem. J. 347 (Pt 1) (2000)
131–138.
[16] R.S. Chanthaphavong, P.A. Loughran, T.Y. Lee, M.J. Scott, T.R. Billiar, A role for cGMP
in inducible nitric-oxide synthase (iNOS)-induced tumor necrosis factor (TNF)
alpha-converting enzyme (TACE/ADAM17) activation, translocation, and TNF receptor
1 (TNFR1) shedding in hepatocytes, J. Biol. Chem. 287 (2012) 35887–35898.
[17] D.J. Killock, A. Ivetic, The cytoplasmic domains of TNFalpha-converting enzyme
(TACE/ADAM17) and L-selectin are regulated differently by p38 MAPK and PKC to
promote ectodomain shedding, Biochem. J. 428 (2010) 293–304.
[18] S. Rousseau, M. Papoutsopoulou, A. Symons, D. Cook, J.M. Lucocq, A.R. Prescott, A.
O'Garra, S.C. Ley, P. Cohen, TPL2-mediated activation of ERK1 and ERK2 regulates
the processing of pre-TNF alpha in LPS-stimulated macrophages, J. Cell Sci. 121
(2008) 149–154.
[19] P. Xu, R. Derynck, Direct activation of TACE-mediated ectodomain shedding by p38
MAP kinase regulates EGF receptor-dependent cell proliferation, Mol. Cell 37 (2010)
551–566.
[20] P. Xu, J. Liu, M. Sakaki-Yumoto, R. Derynck, TACE activation by MAPK-mediated
regulation of cell surface dimerization and TIMP3 association, Sci. Signal. 5 (2012)
ra34.
[21] Q. Zhang, S.M. Thomas, V.W. Lui, S. Xi, J.M. Siegfried, H. Fan, T.E. Smithgall, G.B. Mills,
J.R. Grandis, Phosphorylation of TNF-alpha converting enzyme by gastrin-releasing
3367J. Schwarz et al. / Biochimica et Biophysica Acta 1833 (2013) 3355–3367peptide induces amphiregulin release and EGF receptor activation, Proc. Natl. Acad.
Sci. U. S. A. 103 (2006) 6901–6906.
[22] S.M. Soond, B. Everson, D.W. Riches, G. Murphy, ERK-mediated phosphorylation of
Thr735 in TNFalpha-converting enzyme and its potential role in TACE protein
trafﬁcking, J. Cell Sci. 118 (2005) 2371–2380.
[23] O. Rosso, T. Piazza, I. Bongarzone, A. Rossello, D. Mezzanzanica, S. Canevari, A.M.
Orengo, A. Puppo, S. Ferrini, M. Fabbi, The ALCAM shedding by the metalloprotease
ADAM17/TACE is involved in motility of ovarian carcinoma cells, Mol. Cancer Res. 5
(2007) 1246–1253.
[24] K.C. Hall, C.P. Blobel, Interleukin-1 stimulates ADAM17 through a mechanism
independent of its cytoplasmic domain or phosphorylation at threonine 735, PLoS
One 7 (2012) e31600.
[25] S.M. Le Gall, T. Maretzky, P.D. Issuree, X.D. Niu, K. Reiss, P. Saftig, R. Khokha, D.
Lundell, C.P. Blobel, ADAM17 is regulated by a rapid and reversible mechanism
that controls access to its catalytic site, J. Cell Sci. 123 (2010) 3913–3922.
[26] T. Maretzky, W. Zhou, X.Y. Huang, C.P. Blobel, A transforming Src mutant increases
the bioavailability of EGFR ligands via stimulation of the cell-surfacemetalloproteinase
ADAM17, Oncogene 30 (2010) 611–618.
[27] P. Reddy, J.L. Slack, R. Davis, D.P. Cerretti, C.J. Kozlosky, R.A. Blanton, D. Shows, J.J.
Peschon, R.A. Black, Functional analysis of the domain structure of tumor necrosis
factor-alpha converting enzyme, J. Biol. Chem. 275 (2000) 14608–14614.
[28] X. Li, L. Perez, H. Fan, Inhibitory role of TACE/ADAM17 cytotail in protein ectodomain
shedding, World J. Biol. Chem. 2 (2011) 246–251.
[29] X. Li, L. Perez, Z. Pan, H. Fan, The transmembrane domain of TACE regulates protein
ectodomain shedding, Cell Res. 17 (2007) 985–998.
[30] F. Peiretti, M. Canault, P. Deprez-Beauclair, V. Berthet, B. Bonardo, I. Juhan-Vague, G.
Nalbone, Intracellular maturation and transport of tumor necrosis factor alpha
converting enzyme, Exp. Cell Res. 285 (2003) 278–285.
[31] X. Li, Y. Yan, W. Huang, Y. Yang, The study of the inhibition of the recombinant TACE
prodomain to endotoxemia in mice, Int. J. Mol. Sci. 10 (2009) 5442–5454.
[32] C. Adrain, M. Zettl, Y. Christova, N. Taylor, M. Freeman, Tumor necrosis factor
signaling requires iRhom2 to promote trafﬁcking and activation of TACE, Science
335 (2012) 225–228.
[33] D.R. McIlwain, P.A. Lang, T. Maretzky, K. Hamada, K. Ohishi, S.K. Maney, T. Berger, A.
Murthy, G. Duncan, H.C. Xu, K.S. Lang, D. Haussinger, A. Wakeham, A. Itie-Youten, R.
Khokha, P.S. Ohashi, C.P. Blobel, T.W. Mak, iRhom2 regulation of TACE controls
TNF-mediated protection against Listeria and responses to LPS, Science 335 (2012)
229–232.
[34] G.H. Waetzig, P. Rosenstiel, A. Arlt, A. Till, K. Brautigam, H. Schafer, S. Rose-John, D.
Seegert, S. Schreiber, Soluble tumor necrosis factor (TNF) receptor-1 induces apoptosis
via reverse TNF signaling and autocrine transforming growth factor-beta1, FASEB J. 19
(2005) 91–93.
[35] G.H. Waetzig, P. Rosenstiel, S. Nikolaus, D. Seegert, S. Schreiber, Differential p38
mitogen-activated protein kinase target phosphorylation in responders and
nonresponders to inﬂiximab, Gastroenterology 125 (2003) 633–634(author reply
635–636).
[36] G.H. Waetzig, D. Seegert, P. Rosenstiel, S. Nikolaus, S. Schreiber, p38 mitogen-
activated protein kinase is activated and linked to TNF-alpha signaling in inﬂammatory
bowel disease, J. Immunol. 168 (2002) 5342–5351.
[37] A.D.Watts, N.H. Hunt, Y.Wanigasekara, G. Bloomﬁeld, D.Wallach, B.D. Roufogalis, G.
Chaudhri, A casein kinase I motif present in the cytoplasmic domain of members of
the tumour necrosis factor ligand family is implicated in ‘reverse signalling’, EMBO J.
18 (1999) 2119–2126.
[38] P. Cassonnet, C. Rolloy, G. Neveu, P.O. Vidalain, T. Chantier, J. Pellet, L. Jones, M.
Muller, C. Demeret, G. Gaud, F. Vuillier, V. Lotteau, F. Tangy, M. Favre, Y. Jacob,
Benchmarking a luciferase complementation assay for detecting protein complexes,
Nat. Methods 8 (2011) 990–992.
[39] R.B. Trimble, A.L. Tarentino, Identiﬁcation of distinct endoglycosidase (endo)
activities in Flavobacterium meningosepticum: endo F1, endo F2, and endo F3. Endo
F1 and endo H hydrolyze only high mannose and hybrid glycans, J. Biol. Chem.
266 (1991) 1646–1651.
[40] B. Sherry, D.M. Jue, A. Zentella, A. Cerami, Characterization of high molecular weight
glycosylated forms of murine tumor necrosis factor, Biochem. Biophys. Res.
Commun. 173 (1990) 1072–1078.
[41] C. Garbers, N. Janner, A. Chalaris, M.L. Moss, D.M. Floss, D. Meyer, F. Koch-Nolte, S.
Rose-John, J. Scheller, Species speciﬁcity of ADAM10 and ADAM17 proteins in
interleukin-6 (IL-6) trans-signaling and novel role of ADAM10 in inducible IL-6
receptor shedding, J. Biol. Chem. 286 (2011) 14804–14811.
[42] C. Hundhausen, D. Misztela, T.A. Berkhout, N. Broadway, P. Saftig, K. Reiss, D.
Hartmann, F. Fahrenholz, R. Postina, V. Matthews, K.J. Kallen, S. Rose-John, A.
Ludwig, The disintegrin-like metalloproteinase ADAM10 is involved in constitutive
cleavage of CX3CL1 (fractalkine) and regulates CX3CL1-mediated cell–cell adhesion,
Blood 102 (2003) 1186–1195.
[43] C. Hundhausen, A. Schulte, B. Schulz, M.G. Andrzejewski, N. Schwarz, P. von
Hundelshausen, U. Winter, K. Paliga, K. Reiss, P. Saftig, C. Weber, A. Ludwig,
Regulated shedding of transmembrane chemokines by the disintegrin and
metalloproteinase 10 facilitates detachment of adherent leukocytes, J. Immunol.
178 (2007) 8064–8072.
[44] S. Rose-John, ADAM17, shedding, TACE as therapeutic targets, Pharmacol. Res. 71C
(2013) 19–22.
[45] M. Yu, J. Lam, B. Rada, T.L. Leto, S.J. Levine, Double-stranded RNA induces shedding of
the 34-kDa soluble TNFR1 from human airway epithelial cells via TLR3-TRIF-RIP1-
dependent signaling: roles for dual oxidase 2- and caspase-dependent pathways,
J. Immunol. 186 (2011) 1180–1188.[46] J.M. Kyriakis, J. Avruch, Mammalian MAPK signal transduction pathways activated
by stress and inﬂammation: a 10-year update, Physiol. Rev. 92 (2012) 689–737.
[47] T. Obata, G.E. Brown, M.B. Yaffe, MAP kinase pathways activated by stress: the p38
MAPK pathway, Crit. Care Med. 28 (2000) N67–N77.
[48] M. Leitges, M. Plomann, M.L. Standaert, G. Bandyopadhyay, M.P. Sajan, Y. Kanoh,
R.V. Farese, Knockout of PKC alpha enhances insulin signaling through PI3K,
Mol. Endocrinol. 16 (2002) 847–858.
[49] R.H. Adams, A. Porras, G. Alonso, M. Jones, K. Vintersten, S. Panelli, A. Valladares,
L. Perez, R. Klein, A.R. Nebreda, Essential role of p38alpha MAP kinase in
placental but not embryonic cardiovascular development, Mol. Cell 6 (2000)
109–116.
[50] E. Marcello, F. Gardoni, M. Di Luca, I. Perez-Otano, An arginine stretch limits
ADAM10 exit from the endoplasmic reticulum, J. Biol. Chem. 285 (2010)
10376–10384.
[51] Y. Cao, Q. Kang, Z. Zhao, A. Zolkiewska, Intracellular processing of metalloprotease
disintegrin ADAM12, J. Biol. Chem. 277 (2002) 26403–26411.
[52] N.J. Godde, G.M. D'Abaco, L. Paradiso, U. Novak, Efﬁcient ADAM22 surface expression
is mediated by phosphorylation-dependent interaction with 14-3-3 protein family
members, J. Cell Sci. 119 (2006) 3296–3305.
[53] E. Diaz-Rodriguez, J.C. Montero, A. Esparis-Ogando, L. Yuste, A. Pandiella, Extracellular
signal-regulated kinase phosphorylates tumor necrosis factor alpha-converting
enzyme at threonine 735: a potential role in regulated shedding, Mol. Biol. Cell 13
(2002) 2031–2044.
[54] M. Nakagawa, K. Nabeshima, S. Asano, M. Hamasaki, N. Uesugi, H. Tani, Y.
Yamashita, H. Iwasaki, Up-regulated expression of ADAM17 in gastrointestinal
stromal tumors: coexpression with EGFR and EGFR ligands, Cancer Sci. 100
(2009) 654–662.
[55] C.C. Yu, L.L. Tsai, M.L. Wang, C.H. Yu, W.L. Lo, Y.C. Chang, G.Y. Chiou, M.Y. Chou, S.H.
Chiou, miR145 targets the SOX9/ADAM17 axis to inhibit tumor initiating cells and
IL-6-mediated paracrine effects in head and neck cancer, Cancer Res. 73 (2013)
3425–3440.
[56] A. Trad, H.P. Hansen, M. Shomali, M. Peipp, K. Klausz, N. Hedemann, K. Yamamoto, A.
Mauermann, C. Desel, I. Lorenzen, H. Lemke, S. Rose-John, J. Grotzinger, ADAM17-
overexpressing breast cancer cells selectively targeted by antibody-toxin conjugates,
Cancer Immunol. Immunother. 62 (2013) 411–421.
[57] K. Yamamoto, A. Trad, A. Baumgart, L. Huske, I. Lorenzen, A. Chalaris, J. Grotzinger, T.
Dechow, J. Scheller, S. Rose-John, A novel bispeciﬁc single-chain antibody for
ADAM17 and CD3 induces T-cell-mediated lysis of prostate cancer cells, Biochem.
J. 445 (2012) 135–144.
[58] M. Yoda, T. Kimura, T. Tohmonda, H. Morioka, M. Matsumoto, Y. Okada, Y. Toyama,
K. Horiuchi, Systemic overexpression of TNFalpha-converting enzyme does not lead
to enhanced shedding activity in vivo, PLoS One 8 (2013) e54412.
[59] I. Lorenzen, A. Trad, J. Grotzinger,Multimerisationof ADisintegrinAndMetalloprotease
protein-17 (ADAM17) is mediated by its EGF-like domain, Biochem. Biophys. Res.
Commun. 415 (2011) 330–336.
[60] S. Dusterhoft, S. Jung, C.W. Hung, A. Tholey, F.D. Sonnichsen, J. Grotzinger, I. Lorenzen,
The membrane-proximal domain of ADAM17 represents the putative molecular
switch of its shedding activity operated by protein-disulﬁde isomerase, J. Am. Chem.
Soc. 135 (2013) 5776–5781.
[61] S.H. Willems, C.J. Tape, P.L. Stanley, N.A. Taylor, I.G. Mills, D.E. Neal, J. McCafferty, G.
Murphy, Thiol isomerases negatively regulate the cellular shedding activity of
ADAM17, Biochem. J. 428 (2010) 439–450.
[62] Y. Wang, A.H. Herrera, Y. Li, K.K. Belani, B. Walcheck, Regulation of mature
ADAM17 by redox agents for L-selectin shedding, J. Immunol. 182 (2009)
2449–2457.
[63] S.M. Le Gall, P. Bobe, K. Reiss, K. Horiuchi, X.D. Niu, D. Lundell, D.R. Gibb, D. Conrad, P.
Saftig, C.P. Blobel, ADAMs 10 and 17 represent differentially regulated components
of a general shedding machinery for membrane proteins such as transforming
growth factor alpha, L-selectin, and tumor necrosis factor alpha, Mol. Biol. Cell 20
(2009) 1785–1794.
[64] T. Maretzky, S.M. Le Gall, S. Worpenberg-Pietruk, J. Eder, C.M. Overall, X.Y. Huang, Z.
Poghosyan, D.R. Edwards, C.P. Blobel, Src stimulates ﬁbroblast growth factor
receptor-2 shedding by an ADAM15 splice variant linked to breast cancer, Cancer
Res. 69 (2009) 4573–4576.
[65] K. Horiuchi, S. Le Gall, M. Schulte, T. Yamaguchi, K. Reiss, G. Murphy, Y. Toyama, D.
Hartmann, P. Saftig, C.P. Blobel, Substrate selectivity of epidermal growth factor-
receptor ligand sheddases and their regulation by phorbol esters and calcium inﬂux,
Mol. Biol. Cell 18 (2007) 176–188.
[66] A. Chalaris, B. Rabe, K. Paliga, H. Lange, T. Laskay, C.A. Fielding, S.A. Jones, S.
Rose-John, J. Scheller, Apoptosis is a natural stimulus of IL6R shedding and contributes
to the proinﬂammatory trans-signaling function of neutrophils, Blood 110 (2007)
1748–1755.
[67] V. Matthews, B. Schuster, S. Schutze, I. Bussmeyer, A. Ludwig, C. Hundhausen, T.
Sadowski, P. Saftig, D. Hartmann, K.J. Kallen, S. Rose-John, Cellular cholesterol
depletion triggers shedding of the human interleukin-6 receptor by ADAM10 and
ADAM17 (TACE), J. Biol. Chem. 278 (2003) 38829–38839.
[68] M.E. Milla, P.E. Gonzales, J.D. Leonard, The TACE zymogen: re-examining the role of
the cysteine switch, Cell Biochem. Biophys. 44 (2006) 342–348.
[69] T. Jefferson, U. Auf dem Keller, C. Bellac, V.V. Metz, C. Broder, J. Hedrich, A.
Ohler, W. Maier, V. Magdolen, E. Sterchi, J.S. Bond, A. Jayakumar, H. Traupe,
A. Chalaris, S. Rose-John, C.U. Pietrzik, R. Postina, C.M. Overall, C.
Becker-Pauly, The substrate degradome of meprin metalloproteases reveals
an unexpected proteolytic link between meprin beta and ADAM10, Cell Mol.
Life Sci. 70 (2013) 309–333.
